Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intercellular transfer of P-glycoprotein mediates the formation of stable multi-drug resistance in human bladder cancer BIU-87 cells.
|
30967374 |
2019 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway.
|
30349370 |
2018 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that SNPs of NR1I2 and its target genes CYP3A5 and ABCB1 are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer.
|
28676933 |
2017 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of YB-1 was correlated with the expression of p-glycoprotein and p53 in bladder cancer cases (p<0.05).
|
28714514 |
2017 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, IHC staining of human BCa tissue supported our conclusion that the expression of HIF-1α and MDR1 was higher in chemoresistant tissue vs. chemosensitive tissue.
|
26717965 |
2016 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that inhibiting ATR-Chk1 activation with WYC0209 suppresses p-glycoprotein expression and increases cisplatin activity in bladder cancer.
|
26657501 |
2016 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
P-Glycoprotein-mediated multidrug resistance is a frequent event during chemotherapy and a key obstacle for bladder cancer therapy.
|
24601223 |
2014 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report a novel mechanism of anthracycline chemoresistance in bladder cancer in which activated Twist mediates P-gp expression in addition to its antiapoptotic roles.
|
22986993 |
2012 |
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was aimed at examining the local distribution of GSTM1, GSTT1, MDR1, and VEGF gene polymorphisms as possible risk factors contributing to the development of bladder cancer among the population from Canary Islands, Spain.
|
21292509 |
2012 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the molecular mechanism of doxorubicin resistance in bladder cancer with regard to p300.
|
21935574 |
2012 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prospective studies are warranted to define a role for MDR1 and ERCC1 analysis in individualizing multimodality treatment in locally advanced bladder cancer.
|
20689757 |
2010 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, overexpression of the MDR1 gene might be a prognostic marker for intravesical recurrence, whereas methylation of the promoter region negatively regulates MDR1 expression and the appearance of multidrug resistance mediated by P-glycoprotein in bladder cancers.
|
11156211 |
2000 |
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
|
7734314 |
1995 |
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given that mdr1 mRNA levels are increased in a proportion of high-grade bladder tumours that are routinely subjected to chemotherapy, we discuss the possibility that mdr1 mRNA levels may be clinically significant as determinants of chemotherapeutic response and outcome in bladder cancer.
|
7908215 |
1994 |